Nuochengjianhua announced on October 13 that the novel BCL2 inhibitor metocla combined with obutinib independently developed by the company to treat relapsed/refractory marginal lymphoma has been approved by the Drug Evaluation Center of the China Drug Administration to conduct a phase III clinical trial. This is the fifth registered clinical trial approved by Metocla.

Nuochengjianhua announced on October 13 that the novel BCL2 inhibitor metocla combined with obutinib independently developed by the company to treat relapsed/refractory marginal lymphoma has been approved by the Drug Evaluation Center of the China Drug Administration to conduct a phase III clinical trial. This is the fifth registered clinical trial approved by Metocla.